Li, Hongxia
Harrison, Emily B. http://orcid.org/0000-0002-6934-3875
Li, Huizhong
Hirabayashi, Koichi
Chen, Jing
Li, Qi-Xiang http://orcid.org/0000-0002-4673-1234
Gunn, Jared
Weiss, Jared
Savoldo, Barbara
Parker, Joel S.
Pecot, Chad V. http://orcid.org/0000-0002-5250-2999
Dotti, Gianpietro http://orcid.org/0000-0002-2639-8526
Du, Hongwei http://orcid.org/0000-0002-7997-4507
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (R21-CA229938-01A1)
U.S. Department of Defense (W81XWH-18-1-0441)
Article History
Received: 30 January 2021
Accepted: 28 March 2022
First Online: 20 April 2022
Competing interests
: G.D. is a member of the scientific advisory board of Bellicum Pharmaceutical and Catamaran; G.D. and B.S. are consultants for Tessa Therapeutics; G.D. receives research support from Bluebird Bio and Bellicum Pharmaceutical; G.D. and H.D. filed a patent for the CAR targeting B7-H3, the patent number is US10519214, and the title is “Methods and Compositions for Chimeric Antigen Receptor Targeting Cancer Cells”. No potential conflicts of interest were disclosed by the other authors.